(CercleFinance.com) – Novartis announces that the US District Court in Delaware has issued a negative decision regarding the validity of a patent covering Entresto and combinations with sacubitril and valsartan, which will expire in 2025 for its pediatric exclusivity.
Stating that it ‘firmly believes that the combination patent is valid’, the Swiss health group says it will appeal to the United States Court of Appeals for the Federal Circuit to overturn the decision.
Despite the possibility of earlier-than-expected generic entry for Entresto in the U.S., Novartis is maintaining its guidance for full-year 2023, based on the future growth potential of its other key products.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
